UK Markets close in 7 hrs 21 mins

Oscotec Inc. (039200.KQ)

KOSDAQ - KOSDAQ Delayed price. Currency in KRW
Add to watchlist
43,900.00+1,900.00 (+4.52%)
At close: 3:30PM KST

Oscotec Inc.

A Building, Korea Bio Park
9th Floor 700, Daewangpangyo-ro Bundang-gu
Seongnam-si 13488
South Korea
82 3 1628 7666

Full-time employees

Key executives

NameTitlePayExercisedYear born
Sung-Hee SonExec. OfficerN/AN/AN/A
Se-Nyun KimExec. OfficerN/AN/AN/A
Hirose DakashiExec. OfficerN/AN/AN/A
Su-Sung LeeExec. OfficerN/AN/AN/A
So-Jin AhnExec. OfficerN/AN/AN/A
Ju-Won KimExec. OfficerN/AN/AN/A
Jae-Sang LeeExec. OfficerN/AN/AN/A
Sung-Ho ParkExec. OfficerN/AN/A1968
Seung-Chul LeeExec. OfficerN/AN/A1963
Mr. Jeung-Keun KimChief Exec. OfficerN/AN/A1960
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.


Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.

Corporate governance

Oscotec Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.